Unknown Cherry, MD
Medical Oncology · Coos Bay, ORNPI 1689659377
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,691 of the $2,061 with a category attached, or 82.1%. It is spread thinly across 36 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $830 and has fallen 54.0% since, to $382 in 2025.
Across 82 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$203
- Amgen$149
- Johnson & Johnson$139
- Heron Therapeutics, Inc.$137
- AVEO Pharmaceuticals, Inc.$117
- Novartis$105
- plus $1K from 30 others
What the payments were for
- Food & beverage$1,69182%
- Education$37018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,061 in reported general payments places this provider in the 60th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 22 | $643 |
| Anastrozole | 26 | $605 |
| Tamoxifen Citrate | 24 | $470 |
| Alendronate Sodium | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Coos Bay
- Jeff SharmanEugene$264K
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.